Cargando…

Striatal Vulnerability in Huntington’s Disease: Neuroprotection Versus Neurotoxicity

Huntington’s disease (HD) is an autosomal dominant neurodegenerative disease caused by the expansion of a CAG trinucleotide repeat encoding an abnormally long polyglutamine tract (PolyQ) in the huntingtin (Htt) protein. In HD, striking neuropathological changes occur in the striatum, including loss...

Descripción completa

Detalles Bibliográficos
Autores principales: Morigaki, Ryoma, Goto, Satoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5483636/
https://www.ncbi.nlm.nih.gov/pubmed/28590448
http://dx.doi.org/10.3390/brainsci7060063
_version_ 1783245789027368960
author Morigaki, Ryoma
Goto, Satoshi
author_facet Morigaki, Ryoma
Goto, Satoshi
author_sort Morigaki, Ryoma
collection PubMed
description Huntington’s disease (HD) is an autosomal dominant neurodegenerative disease caused by the expansion of a CAG trinucleotide repeat encoding an abnormally long polyglutamine tract (PolyQ) in the huntingtin (Htt) protein. In HD, striking neuropathological changes occur in the striatum, including loss of medium spiny neurons and parvalbumin-expressing interneurons accompanied by neurodegeneration of the striosome and matrix compartments, leading to progressive impairment of reasoning, walking and speaking abilities. The precise cause of striatal pathology in HD is still unknown; however, accumulating clinical and experimental evidence suggests multiple plausible pathophysiological mechanisms underlying striatal neurodegeneration in HD. Here, we review and discuss the characteristic neurodegenerative patterns observed in the striatum of HD patients and consider the role of various huntingtin-related and striatum-enriched proteins in neurotoxicity and neuroprotection.
format Online
Article
Text
id pubmed-5483636
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-54836362017-06-28 Striatal Vulnerability in Huntington’s Disease: Neuroprotection Versus Neurotoxicity Morigaki, Ryoma Goto, Satoshi Brain Sci Review Huntington’s disease (HD) is an autosomal dominant neurodegenerative disease caused by the expansion of a CAG trinucleotide repeat encoding an abnormally long polyglutamine tract (PolyQ) in the huntingtin (Htt) protein. In HD, striking neuropathological changes occur in the striatum, including loss of medium spiny neurons and parvalbumin-expressing interneurons accompanied by neurodegeneration of the striosome and matrix compartments, leading to progressive impairment of reasoning, walking and speaking abilities. The precise cause of striatal pathology in HD is still unknown; however, accumulating clinical and experimental evidence suggests multiple plausible pathophysiological mechanisms underlying striatal neurodegeneration in HD. Here, we review and discuss the characteristic neurodegenerative patterns observed in the striatum of HD patients and consider the role of various huntingtin-related and striatum-enriched proteins in neurotoxicity and neuroprotection. MDPI 2017-06-07 /pmc/articles/PMC5483636/ /pubmed/28590448 http://dx.doi.org/10.3390/brainsci7060063 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Morigaki, Ryoma
Goto, Satoshi
Striatal Vulnerability in Huntington’s Disease: Neuroprotection Versus Neurotoxicity
title Striatal Vulnerability in Huntington’s Disease: Neuroprotection Versus Neurotoxicity
title_full Striatal Vulnerability in Huntington’s Disease: Neuroprotection Versus Neurotoxicity
title_fullStr Striatal Vulnerability in Huntington’s Disease: Neuroprotection Versus Neurotoxicity
title_full_unstemmed Striatal Vulnerability in Huntington’s Disease: Neuroprotection Versus Neurotoxicity
title_short Striatal Vulnerability in Huntington’s Disease: Neuroprotection Versus Neurotoxicity
title_sort striatal vulnerability in huntington’s disease: neuroprotection versus neurotoxicity
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5483636/
https://www.ncbi.nlm.nih.gov/pubmed/28590448
http://dx.doi.org/10.3390/brainsci7060063
work_keys_str_mv AT morigakiryoma striatalvulnerabilityinhuntingtonsdiseaseneuroprotectionversusneurotoxicity
AT gotosatoshi striatalvulnerabilityinhuntingtonsdiseaseneuroprotectionversusneurotoxicity